Navigation Links
Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
Date:11/8/2011

SAN FRANCISCO, Nov. 8, 2011 /PRNewswire/ -- OrbusNeich today announced that three-year clinical outcomes data from the use of the Genous Stent in a large, real-world patient population demonstrate the device's long-term safety and efficacy. These results were published in the October issue of the Journal of Interventional Cardiology.

At three-year clinical follow-up, the study's primary endpoint, a composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR), in an unselected patient population was 18.3%. Between one and three years, TLR had increased by only 3.6%, and no cases of late and very late definite stent thrombosis (ST) were observed.

"This is the first report of three-year clinical outcomes for the Genous Stent, and it is important to recognize that only a small number of studies have ever reported on three-year outcomes following percutaneous coronary intervention with stent placement in an all-comer population," said Margo Klomp, M.D., of the Academic Medical Center, Amsterdam, and lead author of the publication. "The target lesion failure rate of 18.3% in this case is on the lower end of the spectrum versus reported DES outcomes. In addition, late and very late ST was absent in our Genous Stent treated cohort, whereas other registries have reported occurrence of late and very late ST in DES treated patients."

The single-center study included 405 unselected patients with mostly complex lesions with an estimated high risk of restenosis. Specifically, 47% of the patients had multivessel disease, and, of the lesions treated, 75% were type B2/C lesions, 20% were chronic total occlusion (CTO) lesions, and 24% were bifurcated lesions. The average stent length was 24.6 +/- 11.7 mm. Patients were treated with clopidogrel for one month, and 16 patients received clopidogrel for less than one month. The duration of
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
9. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
10. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  Lehigh Valley Health Network has announced the ... adding to its existing arsenal of five 5-foot-5 germ-killing ... within the network, LVHN is now deploying the largest ... superbugs and provide the best possible patient care available. ... TRU-D – the signature product of Memphis ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ... sciences company focused on developing stem cell based therapies ... Weinreb , its President and CEO, will be ... The conference will be held on Thursday, May 30, ... E 42nd Street in New York City.  Mr. Weinreb,s ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... , , , ... academic, private and government cancer drug discovery efforts , ... Research Institute today announced that it has been selected as ... Institute,s (NCI) Chemical Biology Consortium (CBC)--a program meant to coordinate ...
... , , , ... N.J., Aug. 19 Newly published data in The New ... (letrozole tablets) following surgery as an optimal treatment approach versus tamoxifen ... , The data include an analysis from the ...
Cached Medicine Technology:Southern Research to Play Key Role in the Federal Government's Search for New Cancer Therapies 2Southern Research to Play Key Role in the Federal Government's Search for New Cancer Therapies 3Southern Research to Play Key Role in the Federal Government's Search for New Cancer Therapies 4Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 2Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 3Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 4Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 5Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 6Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 7Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 8Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 9
(Date:5/21/2013)... Five million Americans will buy a personal ... Liashek, owner of Studio South Fitness in ... at credentials and experience. The variation in education and ... trainer can pay $69.50 and get certified online in ... invest in themselves, A serious, professional trainer spends close ...
(Date:5/21/2013)... Third Generation Master Barber Greg Zorian is ... barbering DVDs. These DVDs include content from the HowToCutHair.tv ... cosmetology school or are current professionals, will no doubt ... teacher and mentor. , Today’s modern men’s hairstyles have ... 1960’s time period. In order to efficiently provide these ...
(Date:5/21/2013)... Tx. (PRWEB) May 21, 2013 Dallas-based ... peer- reviewed journal article testing the efficacy of their ... of eczema. The clinical study results appear in the ... , The article, “A Novel Sodium Hypochlorite Cleanser Shows ... Atopic Dermatitis,” reports impressive findings seen after consistent use ...
(Date:5/21/2013)... Everspark Interactive, one of the city's leading online ... the past year – and announced another milestone this ... efforts for Kids II, a designer of innovative baby ... local effort, specializing in search engine optimization (SEO) or ... website. The company now offers a host of boutique ...
(Date:5/21/2013)... Greenville, SC (PRWEB) May 21, 2013 ... be bringing the Philips Pocket Memo 8000, the newest ... around the country, providing a top-notch product for anyone ... recorder. The Pocket Memo 8000 is ... area few of the all-new digital voice recorder features ...
Breaking Medicine News(10 mins):Health News:Sarasota Fitness Tips: Choosing a Safe Trainer and Gym 2Health News:Sarasota Fitness Tips: Choosing a Safe Trainer and Gym 3Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 2Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 3Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 4Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 5Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 6Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 2Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 3Health News:Everspark Named Interactive Marketing Company for Kids II 2Health News:DTP Sales & Service Announces Upcoming Availability Of Philips Pocket Memo 8000 Series 2
... ... ... 1, 2010 -- JPay.com, the Trusted Leader in Offender Services, has brought their pioneering ... cost to correctional departments and today announced the newest member of the JPay family, ...
... new study adds to the mounting evidence that older adults ... inadequacy may be a risk factor for the metabolic syndrome, ... were presented at The Endocrine Society,s 92nd Annual Meeting in ... of diabetes and cardiovascular disease, an adequate vitamin D level ...
... ... in the United States we,re still seeing discriminatory actions towards the medicine. ... discrimination as at the young age of 30 he fights Cancer and a ... his job for using medicinal marijuana and the American Civil Liberties Union is ...
... ... to attract patients, compete effectively, grow their revenues, counter the declining economy and prepare ... ... doctor and physician marketing firm Heathcare Success Strategies , doctors are increasingly resorting to ...
... BruxZir Solid Zirconia, ... bridge with no porcelain overlay. This new restoration proves strong, reliable and esthetic because of ... ... innovation from Glidewell Dental Lab , is a full-contour solid zirconia crown or bridge ...
... ... company specializing in threat prevention and cloud based antivirus solutions, announced today the launch ... cross carrier and worldwide with Google reporting 60,000 Android handsets shipped each day., ... (PRWEB) July 1, ...
Cached Medicine News:Health News:JPay, the Apple of Washington State DOC's eye 2Health News:Low vitamin D linked to the metabolic syndrome in elderly people 2Health News:Fired Wal-Mart Employee Accepts Full Scholarship to The Medical Marijuana Academy 2Health News:Doctors and Medical Groups Increasingly Embrace Physician Marketing to Counter Changes in Health Care 2Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 2Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 3Health News:Strength Based on Science Drives Glidewell Dental Lab's BruxZir Solid Zirconia 4Health News:Bluepoint Security Launches World's First Cloud Antivirus For The Google Android Mobile Platform 2
... Cauteries provide a broad selection ... in a wide variety of ... cautery is packaged sterile, complete ... lock switch in the "off ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... Accu-Temp Cauteries provide a broad selection ... a wide variety of ophthalmic procedures. ... sterile, complete with a safety cap ... " position when not in use, ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
Medicine Products: